tbuckley/cabot-search huggingface dataset:
Abnormalities Detected By Array CGH and Fluorescence in Situ Hybridization in AML with Normal Karyotype Lacking Mutations in NPM1, CEBPA, RUNX1 and MLL Partial Tandem Duplications Are Associated with Unfavorable Outcome
Authors: Claudia Haferlach, Kathleen Zieschang, Susanne Schnittger, Tamara Alpermann, Melanie Zenger, Karolína Perglerová, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2015)
SAT0400 Clinical Factors Impacting Statin Usage in A Longitudinal Ankylosing Spondylitis Cohort:
Authors: J. Dau, M. Weisman, M. Lee, M. Ward, M. Brown, L. Diekman, M. Rahbar, L. Gensler, J. Reveille
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with ankylosing spondylitis (AS) are at higher risk for developing cardiovascular comorbidities. While aortic valve and conduction defects are most common, increased levels of LDL cholesterol are also seen. Statin usage has been reported to lower CRP and ESR though the power of these studies are limited due to small sample size and short-term follow-up (1,2). <h3>Objectives</h3> This study examines associations of statin usage with socio-demographic and clinical factors, including disease activity, functional impairment, and radiographic severity in patients with two years of follow-up or more. <h3>Methods</h3> 655 AS patients meeting modified New York criteria followed at least 2 years (and up to 12 years) were included in the analysis. Demographic and clinical parameters (disease activity and functional impairment were collected every 6 months, as well as radiographic assessments (BASRI and mSASSS) every 2 years. Univariable and multivariable mixed effect models were developed to identify independent factors associated with statin usage over time. <h3>Results</h3> Mean disease duration was 18 years (SD=13). 10% (n=66) of the cohort were using statins. Univariable longitudinal regression models are shown below: Multivariable longitudinal analyses controlling for confounders showed independent associations of age &gt;40 years (p&lt;0.001, OR=5.5 (2.3, 13.3)), the presence of cardiovascular disease (p&lt;0.001, OR=7.6 (3.8, 15.5)), diabetes (p=0.01, OR=4.7 (1.4, 15.4)), opiate use (p=0.03, OR=2.0 (1.1, 3.7)), and CRP (p=0.03, OR=0.4 (0.2, 0.9)). <h3>Conclusions</h3> Statin usage was, as expected, more likely in those of older age with greater disease duration and greater radiographic severity. Even though statins are known to reduce CRP, the association with markers of lower disease activity, both subjective (BASDAI on univariable analysis) and objective (CRP on both univariable and multivariable analyses), raises the possibility of a role in suppressing inflammation in patients with AS. <h3>References</h3> Heinemann S and Daemen M. Cardiovascular risks in spondyloarthropaties. Curt Opin Rheumatol. 2007 19:358–362. Denderen JC, Peters MJL, van Halm VP, van de Horst-Bruinsma, Dijkmans BAC, Nurmohamed MT. Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rhem Dis. 2006; 65: 695–696. <h3>Disclosure of Interest</h3> J. Dau: None declared, M. Weisman Grant/research support from: UCB, Human Genome Sciences, Sanofi, Eli Lilly and Co, Genentech, Inc., Santarus Inc., EMD Serono, ChemoCentryx, GSK, Immunomedics Inc., Consultant for: Boehringer Ingelheim/Proskauer, Ardea Biosciences, Epirus Biopharmaceuticals, Acerta Pharma, M. Lee: None declared, M. Ward: None declared, M. Brown: None declared, L. Diekman: None declared, M. Rahbar: None declared, L. Gensler: None declared, J. Reveille: None declared
PTH-145 Cirrhosis Screening with A Portable Fibroscan® Device in a Community Alcohol Support Service: Feasibility Study
Authors: K Matthews, A MacGilchrist, M Coulter Smith, R Cetnarskyj
Journal: Gut (2016)

<h3>Introduction</h3> Alcohol misuse is the major cause of the increase in deaths from liver disease in the UK,<sup>1</sup> particularly in Scotland<sup>2</sup> and particularly in areas of social deprivation. Liver disease usually presents late, with advanced liver disease and cirrhosis often asymptomatic.<sup>3</sup> Patients with alcohol misuse in areas of social deprivation are a “hard to reach” population. This study assessed the feasibility of using a portable Fibroscan® to measure transient elastography (TE), a non-invasive method of assessing hepatic fibrosis, as a screening tool within a community alcohol support service. The study monitored the uptake of a Fibroscan® in individuals accessing one community alcohol support service in a deprived area; determined the apparent prevalence of undiagnosed fibrosis/cirrhosis in participants over a 6 month period; and monitored engagement following referral to specialist liver services of those individuals with TE &gt; 7 kPa. <h3>Methods</h3> Numbered research information packs were issued on request to individuals who self-identified as harmful drinkers. Consented individuals with a TE &gt; 7 kPa were referred to a nurse-led service within the community service for further tests; results of which determined onward referral to a liver specialist. Participants were monitored for compliance with appointments and follow-up interventions. <h3>Results</h3> 118 research packs issued with 79 participants: (67%) uptake. 3 unreliable Fibroscan® results (n = 76). 20 (26%) participants had a reading &gt;7 kPa requiring referral to nurse led service. 12 (16%) with indications of significant liver disease requiring onward referral to liver specialist including 5 (7%) indicative of cirrhosis.19/20 (95%) participants requiring referral to nurse led service attended for further investigations.11/12 (92%) participants requiring onward referral to specialist services attended initial appointment. <h3>Conclusion</h3> A 67% uptake suggests a nurse led Fibroscan® service in a community alcohol service is acceptable. Early indications show a high compliance with liver services offering potential for early intervention and improved health outcomes. <h3>References</h3> 1 British Association for the Study of the Liver and British Society of Gastroenterology 2009. <i>The National Plan for Liver Services. A time to act: improving liver health and outcomes in liver disease.</i> 2 Scottish Public Health Observatory 2015<i>. Public Health Information for Scotland.</i> 3 Williams R, <i>et al.</i> Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. <i>Lancet. </i> 2014;<b>384:</b>1953–1997. <h3>Disclosure of Interest</h3> None Declared
Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.
Authors: Michele Milella, Maria Rosaria Ricciardi, Chiara Gregorj, Fabiana De Cave, Steven L. Abrams, Linda S. Steelman, Sabina Chiaretti, Marina Konopleva, Maria Teresa Petrucci, Francesco Cognetti, Robert Foa, Michael Andreeff, James McCubrey, Agostino Tafuri
Journal: Blood (2006)
Clinical and molecular features of adenovirus type 2, 3, and 7 infections in children in an outbreak in Taiwan, 2011
Authors: M.-R. Lin, S.-L. Yang, Y.-N. Gong, C.-C. Kuo, C.-H. Chiu, C.-J. Chen, Y.-C. Hsieh, C.-Y. Kuo, C.-W. Fang, K.-C. Tsao, Y.-C. Huang
Journal: Clinical Microbiology and Infection (2016)
Pharmcokinetics of Fondaparinux by Anti-Xa Levels and Clinical Response to Anticoagulation in a 4-Month Old Congenital Cardiac Patient with Heparin-Induced Thrombocytopenia (HIT) and Established Venous Thrombosis Transitioned from Argatroban to Fondaparinux.
Authors: Lynn K. Boshkov, Aileen Kirby, Melinda Heuschkel
Journal: Blood (2004)
Trend Analysis of Clinical Outcomes in Hodgkin Lymphoma over the Last Three Decades: Report from the Nebraska Lymphoma Study Group
Authors: Kailash Mosalpuria, Fausto R Loberiza, R. Gregory Bociek, Matthew A. Lunning, Apar Kishor Ganti, James Olen Armitage, Julie M. Vose, Philip Bierman
Journal: Blood (2014)
Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.
Authors: Nizar J. Bahlis, Kevin Song, Young Trieu, Birgitte Roland, Esther Masih-Khan, Hong Chang, Helene Bruyere, Adnan Mansoor, Douglas Horsman, Michael Eliasziw, Douglas Stewart, Donna Reece
Journal: Blood (2007)
Deciphering the Heterogeneity of 13q Deletions in CLL on the Cytogenetic and Molecular Level by SNP Arrays: In 49% of Cases Deletion Breakpoints Cluster in a 200 Kb Sized Region on the Centromeric Side and in a 300 Kb Sized Region on the Telomeric Side
Authors: Claudia Haferlach, Alexander Kohlmann, Sonja Rauhut, Frank Dicker, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach
Journal: Blood (2008)
PTH-129 Machine Learning Creates A Simple Endoscopic Classification System that Improves Dysplasia Detection in Barrett’s Oesophagus in Non-Expert Endoscopists
Authors: V Sehgal, A Rosenfeld, D Graham, G Lipman, R Bisschops, K Ragunath, M Banks, R Haidry, L Lovat
Journal: Gut (2016)

<h3>Introduction</h3> Barrett’s Oesophagus (BE) is the pre-cursor to oesophageal adenocarcinoma. Endoscopic surveillance is performed to detect dysplasia in BE as it is likely to be treatable. Machine Learning (ML) is a technology that generates simple rules, known as a Decision Tree (DT). Using a DT generated from Expert Endoscopists (EE), we hypothesised that this could be used to improve dysplasia detection in Non-Expert Endoscopists (NEE). <h3>Methods</h3> Endoscopic videos of Non-Dysplastic (ND-BE) and Dysplastic (D-BE) BE were recorded. Areas of interest were biopsied. Videos were shown to 3 EE (blinded) who interpreted mucosal &amp; vascular patterns, presence of nodularity/ulceration &amp; suspected diagnosis. Acetic Acid (ACA) was sometimes used. EE answers were inputted into the WEKA package to identify the most important attributes and generate a DT to predict dysplasia. NEE (GI registrars and medical students) scored these videos online before &amp; after online training using the DT (Fig 1). Outcomes were calculated before &amp; after training. Student’s t-test was used (p &lt; 0.05). <h3>Results</h3> Videos from 40 patients (11 pre/post ACA) were collected (23 ND-BE, 17 D-BE). EE mean accuracy of dysplasia prediction was 96% using the DT. Mean sensitivity/specificty were 93%/99%. Neither vascular pattern nor ACA improved dysplasia detection. Students had a high sensitivity but poor specificity as they ‘overcalled’ normal areas. GI registrars did the opposite. Training significantly improved sensitivity of dysplasia detection amongst registrars without loss of specificity. (Table 1). Specificity rose in students without loss of sensitivity and significant improvement in overall detection. <h3>Conclusion</h3> ML can generate a simple algorithm from EE to accurately predict dysplasia. Once taught to NEE, it yields a significantly higher rate of dysplasia detection. This opens the door to standardised training and assessment of competence in those performing endoscopy in BE. <h3>Disclosure of Interest</h3> None Declared
Evolving Approaches for Statins in Primary Prevention
Authors: Ann Marie Navar, Eric D. Peterson
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Social care is “most urgent” priority for autumn statement, say leading think tanks
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Leading think tanks have urged ministers to boost social care funding to safeguard the care of older and disabled people

ALAMY

The government should prioritise social care ahead of the NHS in its upcoming autumn statement, three leading UK think tanks have urged.

In a joint briefing paper published ahead of the government’s autumn statement on 23 November, the Nuffield Trust, the King’s Fund, and the Health Foundation said that the beleaguered social care sector faced a £1.9bn (€2.1bn; $2.4bn) funding gap next year through cuts and rising demand.1

Though acknowledging the substantial pressure on NHS budgets, the think tanks argued that plugging the social …
The SRL peptide of rhesus rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia
Authors: Sujit K. Mohanty, Bryan Donnelly, Inna Lobeck, Ashley Walther, Phylicia Dupree, Abigail Coots, Jaroslaw Meller, Monica McNeal, Karol Sestak, Greg Tiao
Journal: Hepatology (2016)

Biliary atresia (BA) is a neonatal obstructive cholangiopathy that progresses to end‐stage liver disease, often requiring transplantation. The murine model of BA, employing rhesus rotavirus (RRV), parallels human disease and has been used to elucidate mechanistic aspects of a virus induced biliary cholangiopathy. We previously reported that the RRV VP4 gene plays an integral role in activating the immune system and induction of BA. Using rotavirus binding and blocking assays, this study elucidated how RRV VP4 protein governs cholangiocyte susceptibility to infection both in vitro and in vivo in the murine model of BA. We identified the amino acid sequence on VP4 and its cholangiocyte binding protein, finding that the sequence is specific to those rotavirus strains that cause obstructive cholangiopathy. Pretreatment of murine and human cholangiocytes with this VP4‐derived peptide (TRTRVSRLY) significantly reduced the ability of RRV to bind and infect cells. However, the peptide did not block cholangiocyte binding of TUCH and Ro1845, strains that do not induce murine BA. The SRL sequence within TRTRVSRLY is required for cholangiocyte binding and viral replication. The cholangiocyte membrane protein bound by SRL was found to be Hsc70. Inhibition of Hsc70 by small interfering RNAs reduced RRV's ability to infect cholangiocytes. This virus‐cholangiocyte interaction is also seen in vivo in the murine model of BA, where inoculation of mice with TRTRVSRLY peptide significantly reduced symptoms and mortality in RRV‐injected mice. Conclusion : The tripeptide SRL on RRV VP4 binds to the cholangiocyte membrane protein Hsc70, defining a novel binding site governing VP4 attachment. Investigations are underway to determine the cellular response to this interaction to understand how it contributes to the pathogenesis of BA. (H epatology 2017;65:1278‐1292)
SP0090 Risk of bias When Reporting A Trial
Authors: H. Yazici
Journal: Annals of the Rheumatic Diseases (2016)

While it is given that some or all of the biases involved in the design and the implementation of a trial are carried to the reporting, our concern in this talk is a list of biases more specific for this stage. I propose that the common denominator in this list is the "urge to prove" (1). One important outcome of this urge is the relative reluctance of the authors to acknowledge the limitations of their work. It is interesting to note that this reluctance is more pronounced in basic science (2) while it has even been said that the main purpose of the discussion sections should be authors discussing limitations of their work, naturally best known to them (3). Another manifestation of the same urge has to do with the pervasive mistaken or ill-use of the p values. As yet again brought up recently (4), the medical literature, for decades, has been replete with articles about this misconception. Physicians and investigators, with no apparent differences between the clinicians and the basic scientists, have singularly been reluctant to correctly understand and use the p value. The main elements of the said misconception seem to be a. Inadequacy in formal probabilistic thinking, the most common being that a p value represents the probability of our trial results being false positive while it actually represents the probability of obtaining the actual trial results had it been they were only due to chance; b. The power of a test is not only important in avoiding a Type II but also a Type I error; c. The information we get from any one p value much depends on the pre-test probabilities of what we try to measure in the study design in which we do this, i.e., an observational or a cross sectional study versus a placebo controlled randomized clinical trial (5). Publication bias traditionally referred to as the athors9 and journal editors9 propensity to publish positive or otherwise <i>striking</i> results. Recently this has been re-considered (6) and the proposal has been that a myriad of other biases, perhaps even including almost all items related to the "urge to prove" might also be included under this broader definition of a publication bias, and again perhaps now better called a 9dissemination bias9. Although much discussed this bias remains rather difficult to accurately identify and quantitate. Finally it has to be remembered, like all biases, the biases involved when reporting a trial can either be unintentional or intentional and this is equally difficult to differentiate and quantify. <h3>References</h3> Yazici H. et al. Bull Hosp Jt Dis, 2013 Yazici H et al. J Clin Epidemiol, 2014 Puhan MA et al. Health Qual Life Outcomes, 2012 Halsey LG et al. Nat Methods 2015 Browner WS et al. JAMA, 1987 Meerpohl et al. BMJ Open, 2015 <h3>Disclosure of Interest</h3> None declared
FRI0587 Evaluation of The Immune Response To Vaccines in Patients on Biological Therapy. Preliminary Data of Rier Study
Authors: P. Richi, T. Navío, L. Cebrian, L. Lojo, L. Gonzalez, M. Salido, P. Castro, A. Jiménez, M.D. Martín, J. Yuste, J. Llorente, I. Thuissard, D. Sanz, S. Muñoz-Fernández
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatic diseases on biological therapy have a greater risk of infections. Vaccination recommendations have been established, but, the effectiveness of vaccines in these patients is not well known, and it seems to depend on the different types of treatment used. <h3>Objectives</h3> To evaluate the response of vaccines against A and B Influenza, hepatitis B and pneumococcus in patients on biological treatment. <h3>Methods</h3> Patients with inflammatory arthopathies, psoriasis (Pso), inflammatory bowel disease (IBD) or connective tissue diseases (CTD) that were on or were going to initiate biological therapy, were included. A and B influenza antibodies (Ab) were measured by ELISA. A good response was achieved when base-line titer was increased by four. Hepatitis B surface antibody (Hep B sAb) was measured by ELISA and considered positive with a final titer &gt;10m IU/ml. Protection against pneumococcus serotypes 1, 3, 7F, 14, 19A and 19F was measured by an opsonophagocytosis killing assay (OPKA). Opsonization titers (OT) were defined as the serum dilution that kills 50% of bacteria. <h3>Results</h3> 280 subjects were included, 167 women (59.6%), with a average age of 49.5±13.2 years. 35% were Rheumatoid Arthritis patients, 33.9% had spondiloarthropathies, 16.8% Psoriatic Arthritis, 5.4% Pso, 2.9% IBD and 6% other diagnostics. 84% of patients were on anti-tumor necrosis factor therapies, 8.9% on Rituximab, 5% on tocilizumab, 1.4% on abatacept and 1.4% received other biologics. 45.4% of subjects were also on DMARDs and 18% on corticosteroids. A good response to influenza A vaccine was achieved in only 3.7% of patients for A influenza and 3.2% for type B, even though the majority of patients showed detectable titers of Ab in sera. 75% of patients had been vaccinated against hepatitis B before beginning the biological therapy. More than 90% of patients vaccinated against hepatitis B during the study achieved a good response. 40% of subjects showed OT against 3 or more pneumococcal serotypes. <h3>Conclusions</h3> The response from patients on biological therapy to the influenza vaccine is lower than expected. Comparative studies between these patients and those without biological treatment and healthy people are needed. There is a considerable amount of patients that have not received hepatitis B vaccine before the beginning of the biological treatment, although the response to this vaccine is good. Pneumococcal vaccine is successful in a considerable proportion of subjects. It is worth insisting on its administration. <h3>Disclosure of Interest</h3> None declared
An Emerging Role for Imaging White Matter in the Preclinical Risk for Alzheimer Disease
Authors: Gene E. Alexander
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal